216 related articles for article (PubMed ID: 24111860)
1. Incretin-based therapies: facing the realities of benefits versus side effects.
Lebovitz HE
Diabetes Technol Ther; 2013 Nov; 15(11):909-13. PubMed ID: 24111860
[No Abstract] [Full Text] [Related]
2. Incretin-based therapies for type 2 diabetes mellitus: a review of direct comparisons of efficacy, safety and patient satisfaction.
Russell S
Int J Clin Pharm; 2013 Apr; 35(2):159-72. PubMed ID: 23263796
[TBL] [Abstract][Full Text] [Related]
3. The potential risks of pancreatitis and pancreatic cancer with GLP-1-based therapies are far outweighed by the proven and potential (cardiovascular) benefits.
Ryder RE
Diabet Med; 2013 Oct; 30(10):1148-55. PubMed ID: 24073725
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of long-acting glucagon-like peptide-1 receptor agonists compared with exenatide twice daily and sitagliptin in type 2 diabetes mellitus: a systematic review and meta-analysis.
Pinelli NR; Hurren KM
Ann Pharmacother; 2011 Jul; 45(7-8):850-60. PubMed ID: 21730278
[TBL] [Abstract][Full Text] [Related]
5. Differentiating among incretin therapies: a multiple-target approach to type 2 diabetes.
Cornell S
J Clin Pharm Ther; 2012 Oct; 37(5):510-24. PubMed ID: 22436069
[TBL] [Abstract][Full Text] [Related]
6. Q: Do incretin drugs for type 2 diabetes increase the risk of acute pancreatitis?
Olansky L
Cleve Clin J Med; 2010 Aug; 77(8):503-5. PubMed ID: 20682512
[No Abstract] [Full Text] [Related]
7. Incretin treatment and risk of pancreatitis in patients with type 2 diabetes mellitus: systematic review and meta-analysis of randomised and non-randomised studies.
Li L; Shen J; Bala MM; Busse JW; Ebrahim S; Vandvik PO; Rios LP; Malaga G; Wong E; Sohani Z; Guyatt GH; Sun X
BMJ; 2014 Apr; 348():g2366. PubMed ID: 24736555
[TBL] [Abstract][Full Text] [Related]
8. Incretins: their physiology and application in the treatment of diabetes mellitus.
Tasyurek HM; Altunbas HA; Balci MK; Sanlioglu S
Diabetes Metab Res Rev; 2014 Jul; 30(5):354-71. PubMed ID: 24989141
[TBL] [Abstract][Full Text] [Related]
9. Risk of Pancreatitis With Incretin Therapies Versus Thiazolidinediones in the Veterans Health Administration.
Wilhite K; Reid JM; Lane M
Ann Pharmacother; 2024 Jul; 58(7):685-689. PubMed ID: 37881914
[TBL] [Abstract][Full Text] [Related]
10. New strategy for the treatment of type 2 diabetes mellitus with incretin-based therapy.
Namba M; Katsuno T; Kusunoki Y; Matsuo T; Miuchi M; Miyagawa J
Clin Exp Nephrol; 2013 Feb; 17(1):10-5. PubMed ID: 23135865
[TBL] [Abstract][Full Text] [Related]
11. The role of incretin-based therapies in the management of type 2 diabetes.
Bandyopadhyay P
Drug News Perspect; 2009 Nov; 22(9):559-67. PubMed ID: 20072733
[TBL] [Abstract][Full Text] [Related]
12. Incretin-mimetic therapies and pancreatic disease: a review of observational data.
Suarez EA; Koro CE; Christian JB; Spector AD; Araujo AB; Abraham S
Curr Med Res Opin; 2014 Dec; 30(12):2471-81. PubMed ID: 25180611
[TBL] [Abstract][Full Text] [Related]
13. Incretin-based glucose-lowering medications and the risk of acute pancreatitis and/or pancreatic cancer: Reassuring data from cardio-vascular outcome trials.
Nauck MA; Meier JJ; Schmidt WE
Diabetes Obes Metab; 2017 Sep; 19(9):1327-1328. PubMed ID: 28432752
[No Abstract] [Full Text] [Related]
14. Using real-world data to evaluate the association of incretin-based therapies with risk of acute pancreatitis: a meta-analysis of 1,324,515 patients from observational studies.
Wang T; Wang F; Gou Z; Tang H; Li C; Shi L; Zhai S
Diabetes Obes Metab; 2015 Jan; 17(1):32-41. PubMed ID: 25200423
[TBL] [Abstract][Full Text] [Related]
15. Extra-pancreatic effects of incretin-based therapies: potential benefit for cardiovascular-risk management in type 2 diabetes.
van Genugten RE; Möller-Goede DL; van Raalte DH; Diamant M
Diabetes Obes Metab; 2013 Jul; 15(7):593-606. PubMed ID: 23216746
[TBL] [Abstract][Full Text] [Related]
16. Beyond glycemic control: cardiovascular effects of incretin-based therapies.
Angeli FS; Shannon RP
Front Horm Res; 2014; 43():144-57. PubMed ID: 24943305
[TBL] [Abstract][Full Text] [Related]
17. Incretin-based agents in type 2 diabetic patients at cardiovascular risk: compare the effect of GLP-1 agonists and DPP-4 inhibitors on cardiovascular and pancreatic outcomes.
Zhang Z; Chen X; Lu P; Zhang J; Xu Y; He W; Li M; Zhang S; Jia J; Shao S; Xie J; Yang Y; Yu X
Cardiovasc Diabetol; 2017 Mar; 16(1):31. PubMed ID: 28249585
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of incretin based therapies: clinical trial data.
White J
J Am Pharm Assoc (2003); 2009; 49 Suppl 1():S30-40. PubMed ID: 19801363
[TBL] [Abstract][Full Text] [Related]
19. Incretin-based therapies are associated with acute pancreatitis: Meta-analysis of large randomized controlled trials.
Roshanov PS; Dennis BB
Diabetes Res Clin Pract; 2015 Dec; 110(3):e13-7. PubMed ID: 26643128
[TBL] [Abstract][Full Text] [Related]
20. Incretin-based therapies for type 2 diabetes mellitus.
Lovshin JA; Drucker DJ
Nat Rev Endocrinol; 2009 May; 5(5):262-9. PubMed ID: 19444259
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
